News Sentiment

OGN sentiment intelligence

Organon & Co news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 60 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 13.52 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

-0.2% over one week, +0.6% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 0.6% over four weeks
Fair value 0.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 11
TradingView 6
Business Wire 6
simplywall.st 3
Seeking Alpha 2
MT Newswires 2
Kavout | AI 1

Event Lens

What the news is about

Classified themes
Market update 39
Deals and strategy 14
Earnings 4
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Quartr Direct company coverage

Organon (OGN) Q1 2026 earnings summary

Organon (OGN) reported Q1 2026 revenue of $1.46 billion, a 4% decrease year-over-year, despite net income rising by 68% to $146 million and diluted EPS reaching $0.55. The company is in the process of being acquired by Sun Pharma for $14.00 per share, with the merger expected to

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 21:11
Source
Quartr
Business Standard Direct company coverage

SBI joins global banks to fund Sun Pharma's $11.75 billion Organon buy

State Bank of India (SBI) is participating with 10 other global banks to finance Sun Pharmaceutical's $11.75 billion acquisition of US-based Organon & Co. The deal, announced in April, is largely debt-funded, with each of the 11 banks committing around $1 billion. This acquisitio

Tone
Positive 71/100
Event
Deals and strategy
Published
07 Jul 2026 17:40
Source
Business Standard
Stock Titan Direct company coverage

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

Organon announced it will present new analysis of pooled Phase 3 data for VTAMA cream (tapinarof) at the 2026 Society for Pediatric Dermatology Annual Meeting. The presentation will evaluate the efficacy and safety of VTAMA cream across age groups in pediatric and adult patients

Tone
Positive 62/100
Event
Market update
Published
07 Jul 2026 11:40
Source
Stock Titan
Market source Direct company coverage

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Organon (OGN) has garnered significant investor attention, with its stock returning +1.1% over the past month, outperforming the S&P 500. The company's earnings estimates for the current and next fiscal years indicate a mixed outlook, with a Zacks Rank #3 (Hold) suggesting it may

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 12:41
Source
Market source
AD HOC NEWS Direct company coverage

Organon & Co highlights its women’s health focus as a standalone company

Organon & Co positions itself as a global women's health specialist after spinning off from a larger pharmaceutical group. The company strategically focuses on contraception, fertility, and established medicines to generate steady cash flows for reinvestment and innovation. Its d

Tone
Positive 72/100
Event
Balance sheet
Published
02 Jul 2026 15:58
Source
AD HOC NEWS
ChartMill Direct company coverage

ORGANON & CO (OGN) Stock Chart

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 00:14
Source
ChartMill
Insider Monkey Direct company coverage

Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?

Organon & Co. (OGN) is expanding its presence in women's health with the upcoming launch of MIUDELLA, a new hormone-free copper IUD, and through an expanded partnership with Samsung Bioepis for a biosimilar therapy in Canada. Though the article notes the potential of OGN, it also

Tone
Positive 66/100
Event
Deals and strategy
Published
30 Jun 2026 13:40
Source
Insider Monkey
TradingView Direct company coverage

Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP

This article provides financial information for Organon & Co. (MUN:7XP), specifically focusing on its enterprise value to EBITDA forward. It details the company's financials on the Munich Stock Exchange, indicating market status and offering access to various financial data point

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:14
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Organon & Co. – NYSE:OGN

This article provides the "Price to earnings forward" value for Organon & Co. (NYSE: OGN). It indicates the value is zero and notes that the market is currently closed with no trades. The content is presented within the context of financial data provided by TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 10:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Organon & Co. – NYSE:OGN

This article presents financial data for Organon & Co. (NYSE: OGN), specifically focusing on its price-to-sales forward metric. Although no specific values are provided in the content itself, the article indicates that this data is available and is part of a larger financial over

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Organon & Co. – LSE:0A9W

This article provides a financial snapshot of Organon & Co. (LSE:0A9W) focusing on its price-to-book forward ratio. It briefly mentions that the market is closed with no trades. The content is primarily a data presentation page from TradingView.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 10:09
Source
TradingView
The Manila Times Direct company coverage

Organon marks 5 years of advancing health through medicines, solutions, partnerships

Organon is celebrating its fifth anniversary, marking a milestone in its mission to expand healthcare access, advance education, and strengthen partnerships. The company emphasizes its commitment to women's health, believing that prioritizing it benefits families and communities.

Tone
Positive 72/100
Event
Market update
Published
27 Jun 2026 06:09
Source
The Manila Times
TradingView Direct company coverage

Organon & Co. Actuals & Estimates (NYSE:OGN)

This article provides a comprehensive overview of Organon & Co. (NYSE: OGN) stock, including current price, historical performance, analyst forecasts, and financial data. It covers actual and estimated earnings, revenue, dividends, market capitalization, and volatility, offering

Tone
Positive 59/100
Event
Earnings
Published
26 Jun 2026 08:40
Source
TradingView
Investing.com Direct company coverage

Organon & Co stock hits 52-week high at $13.49

Organon & Co. (OGN) stock reached a 52-week high of $13.49, reflecting a 36% increase over the past year and significant gains in recent months. Despite this positive momentum and an InvestingPro analysis suggesting the stock is undervalued, the company recently reported first-qu

Tone
Positive 67/100
Event
Market update
Published
25 Jun 2026 13:39
Source
Investing.com
Business Wire Direct company coverage

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited, where shareholders are set to receive $14.00 per share. KSF aims to determine if this consideration and the underlying process are adequate, or i

Tone
Negative 39/100
Event
Market update
Published
24 Jun 2026 18:09
Source
Business Wire
Stock Titan Direct company coverage

Organon puts two Prolia, Xgeva biosimilars on sale in Canada

Organon Canada, in collaboration with Shanghai Henlius Biotech, Inc., has launched two denosumab biosimilars, BILDYOS® and TUZEMTY®, in Canada. These biosimilars are versions of PROLIA and XGEVA, used for treating osteoporosis and bone complications associated with cancer, and ar

Tone
Positive 70/100
Event
Market update
Published
23 Jun 2026 09:11
Source
Stock Titan
grafa.com Direct company coverage

Organon secures global licensing deal for MIUDELLA copper IUD

Organon has secured a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA, a hormone-free copper intrauterine device that is 99% effective. This deal grants Organon exclusive international distribution rights, expanding long-acting reversible birth control options

Tone
Positive 70/100
Event
Deals and strategy
Published
22 Jun 2026 16:10
Source
grafa.com
Stock Titan Direct company coverage

Organon wins rights to first U.S. hormone-free copper IUD in 40 years

Organon has completed a licensing agreement for MIUDELLA®, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD), marking the first such device introduced in the U.S. in over 40 years. MIUDELLA, approved by the FDA in February 2025 and expected to be commercially

Tone
Positive 66/100
Event
Market update
Published
22 Jun 2026 11:30
Source
Stock Titan
Business Wire Direct company coverage

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

Organon has finalized a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA®, a hormone-free, copper intrauterine device (IUD). This FDA-approved device is the first of its kind in over 40 years, offers 99% effectiveness for up to three years, and is anticipated t

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 11:10
Source
Business Wire
Business Wire Direct company coverage

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA

Organon and Samsung Bioepis have expanded their agreement to commercialize PYZCHIVA (ustekinumab), a biosimilar referencing STELARA, in Canada, bringing their collaboration to six biosimilars. PYZCHIVA is indicated for conditions like chronic plaque psoriasis, psoriatic arthritis

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 11:09
Source
Business Wire
KBR Direct company coverage

Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada

Samsung Bioepis and Organon have expanded their partnership, granting Organon commercialization rights in Canada for Pyzchiva, Samsung Bioepis' biosimilar of Stelara (ustekinumab). This addition brings their collaborative biosimilar portfolio in Canada to six products. The agreem

Tone
Positive 72/100
Event
Deals and strategy
Published
19 Jun 2026 10:40
Source
KBR
Businesskorea Direct company coverage

Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in Canada

Samsung Bioepis and Organon have expanded their commercialization agreement in Canada to include PYZCHIVA®, a biosimilar referencing STELARA® for various inflammatory conditions. This agreement deepens their collaboration to six biosimilars across immunology, oncology, and dermat

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 22:39
Source
Businesskorea
Business Wire Direct company coverage

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA®

Organon and Samsung Bioepis have expanded their development and commercialization agreement, granting Organon commercialization rights in Canada for PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA® (ustekinumab). This expands their Canadian biosimilar portfolio to six

Tone
Positive 73/100
Event
Market update
Published
18 Jun 2026 17:39
Source
Business Wire